Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
Wassilak, Steve G.
Pallansch, Mark A.
Sutter, Roland W.
Tuzankina, Irina A.
Costa-Carvalho, Beatriz T. [UNIFESP]
Luis Franco, Jose
Espinosa-Rosales, Francisco J.
McKinlay, Mark A.
Is part ofFrontiers In Immunology
MetadataShow full item record
Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or yearsthe excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame.
CitationFrontiers In Immunology. Lausanne, v. 8, p. -, 2017.
immunodeficiency-associated vaccine-derived polioviruses
oral poliovirus vaccine
SponsorshipBill & Melinda Gates Foundation
- EPM - Artigos 
Showing items related by title, author, creator and subject.
Primary immunodeficiency association with systemic lupus erythematosus: review of literature and lessons learned by the rheumatology division of a tertiary university hospital at sao paulo, brazil Errante, Paolo Ruggero [UNIFESP]; Perazzio, Sandro Felix; Frazao, Josias Brito [UNIFESP]; da Silva, Neusa Pereira; Coelho Andrade, Luis Eduardo [UNIFESP] (Elsevier science inc, 2016)Primary immunodeficiency disorders (PID) represent a heterogeneous group of diseases resulting from inherited defects in the development, maturation and normal function of immune cells
Matida, Luiza Harunari [UNIFESP]; Marcopito, Luiz Francisco [UNIFESP]; Succi, Regina Célia de Menezes [UNIFESP]; Marques, Heloisa Helena de Souza; Della Negra, Marinella; Grangeiro, Alexandre; Hearst, Norman (Brazilian Society of Infectious Diseases, 2004-12-01)Brazil was the first developing country to provide free, universal access to antiretroviral treatment for AIDS patients. The Brazilian experience thus provides the first evidence regarding the impact of such treatment on ...
Costa-Carvalho, Beatriz T. [UNIFESP]; Wandalsen, Gustavo F. [UNIFESP]; Pulici, Guilherme [UNIFESP]; Aranda, Carolina Sanchez [UNIFESP]; Sole, Dirceu [UNIFESP] (Elsevier B.V., 2011-05-01)Objective: the aim of this study was to evaluate pulmonary complications in patients with primary antibody deficiency (X-linked agammaglobulinaemia [XLA] and common variable immunodeficiency [CVID]).Methods: Thirty patients ...